Last updated on August 2018

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

Brief description of study

The null hypothesis of no difference in CR% at 3 months between the arms will be tested against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds ratio for arm yielded by this model.

Detailed Study Description

This is a superiority trial aiming to increase the 3 month complete response rate. The sample size is calculated on the hypothesis that the experimental treatment will increase the 3 months response rate up to 21% (by 3 folds, based on the 7% reported in Scheinberg et al [17]). Under these assumptions, the sample size to reject the null hypothesis is n=96 patients for each treatment arm, increased by 4% for possibly not evaluable patients (total number of 200 patients, 100 each treatment arm). Statistical design for sample size calculation: increase from 7% (control arm) to 21% (investigational arm) in 3 month complete response rate (two-sided binomial test); alpha-error 0.05; power 0.8.

Clinical Study Identifier: NCT02099747

Find a site near you

Start Over


Amsterdam, Netherlands
  Connect »


Groningen, Netherlands
  Connect »


Utrecht, Netherlands
  Connect »

Donostia Hospital

San Sebastian, Spain
  Connect »

City Hospital

Belfast, United Kingdom
  Connect »

St. James Hospital

Leeds, United Kingdom
  Connect »

City Hospital

Nottingham, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.